Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.64 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 3/20 | 0.42 |
| ▸ | PLK4 | O00444 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | MARK3 | P27448 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.42 |
| ▸ | STK3 | Q13188 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901296 | 0.86 | CDC7 (0.56) | CDC7DBF4MAPTSLC6A3TMEM97 | |
| SCHEMBL4903115 | 0.80 | IKBKB (0.60) | CDC7DBF4IKBKBPLK4AURKA | |
| SCHEMBL12969722 | 0.78 | CDC7 (1.00) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4893099 | 0.75 | CDC7 (0.69) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL12969830 | 0.74 | CDC7 (0.58) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4657084 | 0.74 | IKBKB (0.66) | SLC6A3TMEM97IKBKBLIMK1CHUK | |
| SCHEMBL4656555 | 0.71 | SLC6A3 (0.52) | MAPTSLC6A3TMEM97IKBKBCHUK | |
| SCHEMBL4892342 | 0.71 | IKBKB (0.61) | IKBKBCHUKEPHA3 | |
| SCHEMBL12969908 | 0.70 | KDM4E (0.63) | CDC7DBF4MAPTIKBKBPLK4 | |
| SCHEMBL4903351 | 0.70 | CDC7 (0.64) | CDC7DBF4MAPTIKBKBPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | claimed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | claimed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673374-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035537-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | CDC7 1740/4885DBF4 2118/4885MAPT 4573/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | CDC7 1740/4885DBF4 2118/4885MAPT 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.